Abstract
The used first generation protease inhibitors may be hampered by virological failure in partially interferon-sensitive patients.
| Original language | English |
|---|---|
| Pages (from-to) | 233-241 |
| Number of pages | 9 |
| Journal | Digestive and Liver Disease |
| Volume | 47 |
| DOIs | |
| Publication status | Published - 2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Aged
- Antiviral Agents
- Drug Resistance, Viral
- Drug Therapy, Combination
- Drug-resistance
- Female
- Genotype
- Hepacivirus
- Hepatitis C, Chronic
- Humans
- Interferon-alpha
- Linear Models
- Male
- Mathematical modelling
- Middle Aged
- Mutation
- Oligopeptides
- Protease Inhibitors
- Protease inhibitors
- RNA Stability
- RNA, Viral
- Ribavirin
- Treatment Outcome
- Viral Load
- Viral kinetic
- Virus Replication
Fingerprint
Dive into the research topics of 'Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver